Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewLM11A 31 dihydrochloride
Description: Nonpeptide p75NTR ligand; neuroprotective
Chemical Name: (2S,3S)-2-Amino-3-methyl-N-[2-(4-morpholinyl)ethyl]pentanamide dihydrochloride
Purity: ≥95% (HPLC)
Biological Activity for LM11A 31 dihydrochloride
LM11A 31 dihydrochloride is a nonpeptide p75NTR ligand and nerve growth factor (NGF) antagonist. LM11A 31 blocks p75-mediated cell death, inhibits proNGF induced cell death (IC50 = 1-10 nM), increases proliferation and survival of hippocampal neural progenitors and inhibits Aβ-induced cell death (EC50 = 20 nM). In animal models of Alzheimer's disease LM11A 31 prevents and reverses atrophy of cholinergic neurites and reverses Alzheimer's pathology; in models of Huntington's disease LM11A 31 increases survival, reduces the formation of aggregates of mutant huntingtin and neuronal degeneration. Also promotes functional recovery in a mouse model of spinal cord injury. Orally available and brain penetrant.
Technical Data for LM11A 31 dihydrochloride
| M. Wt | 316.27 |
| Formula | C12H25N3O2.2HCl |
| Storage | Desiccate at RT |
| Purity | ≥95% (HPLC) |
| CAS Number | 1243259-19-9 |
| PubChem ID | 91654620 |
| InChI Key | LLIHJRRZJDEKLB-ULEGLUPFSA-N |
| Smiles | O=C([C@@H](N)[C@@H](C)CC)NCCN1CCOCC1.Cl.Cl |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for LM11A 31 dihydrochloride
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| water | 31.63 | 100 | |
| DMSO | 31.63 | 100 |
Preparing Stock Solutions for LM11A 31 dihydrochloride
The following data is based on the product molecular weight 316.27. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 3.16 mL | 15.81 mL | 31.62 mL |
| 5 mM | 0.63 mL | 3.16 mL | 6.32 mL |
| 10 mM | 0.32 mL | 1.58 mL | 3.16 mL |
| 50 mM | 0.06 mL | 0.32 mL | 0.63 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for LM11A 31 dihydrochloride
References for LM11A 31 dihydrochloride
References are publications that support the biological activity of the product.
Shi et al (2013) A small molecule P75NTR ligand protects neurogenesis after traumatic brain injury. Stem Cells [Epub ahead of print] PMID: 23940017
Massa et al (2006) Small, nonpeptide p75NTR ligands induce survival signaling and inhibit proNGF-induced death. J.Neurosci. 26 5288 PMID: 6707781
Tep et al (2013) Oral administration of a small molecule targeted to block proNGF binding to p75 promotes myelin sparing and functional recovery after spinal cord injury. J.Neurosci. 33 397 PMID: 23303920
Simmons et al (2014) A small molecule p75NTR ligand, LM11A-31, reverses cholinergic neurite dystrophy in Alzheimer's disease mouse models with mid- to late-stage disease progression. PLoS One 9 e102136 PMID: 25153701
Simmons et al (2016) A small molecule p75NTR ligand normalizes signalling and reduces Huntington's disease phenotypes in R6/2 and BACHD mice. Hum.Mol.Genet. 25 4920 PMID: 28171570
If you know of a relevant reference for LM11A 31 dihydrochloride, please let us know.
View Related Products by Target
Keywords: LM11A 31 dihydrochloride, LM11A 31 dihydrochloride supplier, LM11A31, dihydrochloride, p75NTR, ligands, selective, NGFR, nerve, growth, factor, receptors, Alzheimer's, Disease, neuroprotective, Trk, Receptors, Neuronal, Metabolism, 5046, Tocris Bioscience
1 Citation for LM11A 31 dihydrochloride
Citations are publications that use Tocris products. Selected citations for LM11A 31 dihydrochloride include:
H Uri et al (2017) p75NTR antagonists attenuate photoreceptor cell loss in murine models of retinitis pigmentosa. Cell Death Dis 8 e2922 PMID: 28703796
Do you know of a great paper that uses LM11A 31 dihydrochloride from Tocris? Please let us know.
Reviews for LM11A 31 dihydrochloride
There are currently no reviews for this product. Be the first to review LM11A 31 dihydrochloride and earn rewards!
Have you used LM11A 31 dihydrochloride?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.